Richard Hardy
University of Utah(US)Huntsman Cancer Institute(US)
Publications by Year
Research Areas
Lung Cancer Research Studies, Neuroendocrine Tumor Research Advances, Genetic factors in colorectal cancer, Neuroblastoma Research and Treatments, Glioma Diagnosis and Treatment
Most-Cited Works
- → Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel(2014)110 cited
- → Capecitabine and streptozocin±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours(2014)69 cited
- → A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications(2012)38 cited
- → A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities(2015)32 cited
- → Blood Thrombogenicity Is Independently Associated With Serum TSH Levels in Post–Non-ST Elevation Acute Coronary Syndrome(2014)25 cited
- → The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study(2016)9 cited
- → Treatment of advanced neuroendocrine tumors: Results of the UKINETS and NCRI randomized phase II NET01 trial.(2012)6 cited
- → Effects of the anti-progestin RU 38486 on rat embryos growing in culture(1991)4 cited
- → Capecitabine and streptozocin ± cisplatin for gastroenteropancreatic neuroendocrine tumours: predictors of long-term survival in the NET01 trial(2016)2 cited
- → Scheduling Nab-Paclitaxel with Gemcitabine (Siege): Randomised Phase Ii Trial to Investigate Two Different Schedules of Nab-Paclitaxel (Abx) Combined with Gemcitabine (Gem) As First Line Treatment for Metastatic Pancreatic Adenocarcinoma (Pdac)(2014)1 cited